Morbidity and long-term results of subcutaneous pyelovesical bypass in chronic ureteral obstruction.


Journal

Progres en urologie : journal de l'Association francaise d'urologie et de la Societe francaise d'urologie
ISSN: 1166-7087
Titre abrégé: Prog Urol
Pays: France
ID NLM: 9307844

Informations de publication

Date de publication:
May 2021
Historique:
received: 17 08 2020
revised: 14 12 2020
accepted: 18 12 2020
pubmed: 19 1 2021
medline: 24 9 2021
entrez: 18 1 2021
Statut: ppublish

Résumé

We present the long-term results and complications of the DETOUR® prosthesis, a permanent subcutaneous pyelovesical bypass for the treatment of ureteral obstruction. Between 2006 et 2018, 34 prosthesis were implanted in 28 patients (mean age 65,8 years) with ureteral obstruction of malignant or benign etiologies. The prosthesis, composed to an inner tube of silicone and an outer tube of expanded polytetrafluoroethylene, is placed subcutaneously between the kidney and the bladder. We are performed infrared spectrophotometry and scanning electron microscopy on two removed prostheses to explore the prosthetic encrustation. The average follow-up was 25,8 months (Maximum: 64 months). Stent revision was required for early bladder fistula in three patients. The major long-term complications were infection (46%), obstruction (3 patients) and bladder fistula (7 patients). The most frequently infection are non-severe, but two patients died from septic shock after fungic colonization of the prosthesis. The infrared spectrophotometry and scanning electron microscopy analysis showed that the obstruction was favored by urinary infection and an alkaline medium. The functional prosthesis rate at 1,2 and 3 years was 94%, 71% and 62%, respectively. The DETOUR® subcutaneous extra-anatomical urinary bypass is an effective and minimally invasive alternative to permanent percutaneous nephrostomy, for both malignant and benign ureteral obstructions in selected patients. 3.

Sections du résumé

BACKGROUND BACKGROUND
We present the long-term results and complications of the DETOUR® prosthesis, a permanent subcutaneous pyelovesical bypass for the treatment of ureteral obstruction.
PATIENTS AND METHODS METHODS
Between 2006 et 2018, 34 prosthesis were implanted in 28 patients (mean age 65,8 years) with ureteral obstruction of malignant or benign etiologies. The prosthesis, composed to an inner tube of silicone and an outer tube of expanded polytetrafluoroethylene, is placed subcutaneously between the kidney and the bladder. We are performed infrared spectrophotometry and scanning electron microscopy on two removed prostheses to explore the prosthetic encrustation.
RESULTS RESULTS
The average follow-up was 25,8 months (Maximum: 64 months). Stent revision was required for early bladder fistula in three patients. The major long-term complications were infection (46%), obstruction (3 patients) and bladder fistula (7 patients). The most frequently infection are non-severe, but two patients died from septic shock after fungic colonization of the prosthesis. The infrared spectrophotometry and scanning electron microscopy analysis showed that the obstruction was favored by urinary infection and an alkaline medium. The functional prosthesis rate at 1,2 and 3 years was 94%, 71% and 62%, respectively.
CONCLUSION CONCLUSIONS
The DETOUR® subcutaneous extra-anatomical urinary bypass is an effective and minimally invasive alternative to permanent percutaneous nephrostomy, for both malignant and benign ureteral obstructions in selected patients.
LEVEL OF EVIDENCE METHODS
3.

Identifiants

pubmed: 33455824
pii: S1166-7087(20)30764-8
doi: 10.1016/j.purol.2020.12.016
pii:
doi:

Types de publication

Journal Article

Langues

eng

Sous-ensembles de citation

IM

Pagination

348-356

Informations de copyright

Copyright © 2021 Elsevier Masson SAS. All rights reserved.

Auteurs

A Nouaille (A)

Department of Urology, Saint Camille Hospital, Bry-sur-Marne, France. Electronic address: amandine.nouaille@gmail.com.

A Descazeaud (A)

Department of Urology, Dupuytren Hospital, University of Limoges, Limoges, France. Electronic address: aureliendescazeaud@gmail.com.

F Desgrandchamps (F)

Department of Urology, Assistance Publique - Hôpitaux de Paris, Hôpital Saint-Louis, Paris, France. Electronic address: francois.desgrandchamps@aphp.fr.

D Bazin (D)

Centre National de la Recherche Scientifique (CNRS), Laboratoire de Chimie Physique, Université Paris XI, Orsay, France. Electronic address: dominique.bazin@u-psud.fr.

M Daudon (M)

Department of Urology, Assistance Publique - Hôpitaux de Paris, Hôpital Tenon, Paris, France. Electronic address: michel.daudon@aphp.fr.

A Masson Lecomte (A)

Department of Urology, Assistance Publique - Hôpitaux de Paris, Hôpital Saint-Louis, Paris, France. Electronic address: amassonlecomte@gmail.com.

P Mongiat-Artus (P)

Department of Urology, Assistance Publique - Hôpitaux de Paris, Hôpital Saint-Louis, Paris, France. Electronic address: pierre.mongiat-artus@aphp.fr.

P Meria (P)

Department of Urology, Assistance Publique - Hôpitaux de Paris, Hôpital Saint-Louis, Paris, France. Electronic address: paul.meria@aphp.fr.

Articles similaires

[Redispensing of expensive oral anticancer medicines: a practical application].

Lisanne N van Merendonk, Kübra Akgöl, Bastiaan Nuijen
1.00
Humans Antineoplastic Agents Administration, Oral Drug Costs Counterfeit Drugs

Smoking Cessation and Incident Cardiovascular Disease.

Jun Hwan Cho, Seung Yong Shin, Hoseob Kim et al.
1.00
Humans Male Smoking Cessation Cardiovascular Diseases Female
Humans United States Aged Cross-Sectional Studies Medicare Part C
1.00
Humans Yoga Low Back Pain Female Male

Classifications MeSH